IL18 and neoplasm: Consistent with these results, the loss of IL-18 with preserved NLRC4 tumor expression (NLRC4hiIL-18lo) was associated with an intermediate survival in comparison with either NLRC4hiIL-18hi or NLRC4loIL-18lo patients (5-year survival rates of 82% for NLRC4hiIL-18hi, 62% for NLRC4hiIL-18lo, and 35% for NLRC4loIL-18lo) (Figure 2D).